Summary: Common weight-loss and diabetes medications, known as GLP-1 receptor agonists (including semaglutide and liraglutide), show comprehensive evidence of tackling the underlying causes of Alzheimer’s disease.
A new review analyzed 30 preclinical studies and found that these drugs consistently reduce the buildup of amyloid-beta and tau, the two toxic proteins that define Alzheimer’s pathology. While human clinical results are still emerging, the research suggests these drugs could serve as a powerful preventative tool against dementia.
Key Facts
- Protein Reduction: In animal and cell studies, 22 research papers showed a reduction in sticky amyloid-beta plaques, while 19 studies found a decrease in harmful tau tangles.
- Liraglutide Leads: Liraglutide emerged as the most extensively studied and consistent performer, effectively reducing both hallmark proteins across multiple trials.
- Preventative Potential: Evidence suggests these drugs are most effective as a preventative measure before cognitive impairment becomes established, rather than as a “cure” for advanced cases.
- Beyond Weight Loss: These drugs likely protect the brain by reducing neuroinflammation, improving brain insulin signaling, and altering the enzymes that produce toxic proteins.
Source: Anglia Ruskin University
A new study has found comprehensive evidence that ‘weight-loss’ GLP-1 receptor agonists such as semaglutide are effective in tackling the biological drivers of Alzheimer’s disease.
The study, published in the journal Molecular and Cellular Neuroscience, examined 30 preclinical studies investigating the effects of four GLP-1 receptor agonists – liraglutide; semaglutide; exenatide; and dulaglutide – on Alzheimer’s disease pathology.
The researchers, from Anglia Ruskin University (ARU), found consistent evidence from animal and cell studies that these drugs, commonly prescribed for people living with type 2 diabetes, reduce the buildup of amyloid‑beta and tau, the two hallmark proteins linked to the development and progression of Alzheimer’s.
The review found 22 studies showed reductions in amyloid‑beta, a protein that forms sticky plaques in the brain. 19 studies found reductions in hyperphosphorylated tau, the form of tau protein that creates harmful tangles within neurons. Liraglutide, the most extensively studied drug, consistently reduced both amyloid‑beta and tau pathology.
Dulaglutide and semaglutide also demonstrated positive effects on these proteins, though fewer studies were available. Exenatide studies yielded mixed results, with some showing reductions in amyloid or tau and others showing no effect.
Evidence in humans is still emerging. Of the two clinical trials that featured in the study, a 26‑week trial of liraglutide found no reduction in amyloid levels or cognitive improvement, but did show preservation of brain glucose metabolism, an indicator of neuronal function.
An 18‑month trial of exenatide showed no significant changes in amyloid or tau in cerebrospinal fluid – the clear liquid that surrounds and protects the brain – but did reduce amyloid‑beta in extracellular vesicles, a potential early biomarker.
Alzheimer’s disease is the most common form of dementia in the UK, affecting around 900,000 people. The number is expected to rise significantly over the next decade. Despite decades of research, effective treatments remain limited.
Lead author Dr Simon Cork, Physiology lead at Anglia Ruskin University’s School of Medicine, said: “This new review provides one of the most comprehensive analyses so far of how GLP‑1 drugs interact with the underlying mechanisms of Alzheimer’s.
“Our study highlights several biological pathways by which GLP‑1 drugs may influence Alzheimer’s, including reducing inflammation, improving insulin signalling in the brain, and altering enzymes involved in the production of amyloid‑beta.
“Whilst human studies demonstrating an impact on cognitive decline are still lacking, the current evidence points towards these drugs having a preventative effect, rather than in patients with established cognitive impairment.
“With more than three‑quarters of preclinical studies showing reductions in amyloid‑beta or tau, and early signals emerging from studies on humans, GLP‑1 drugs remain strong candidates for future Alzheimer’s prevention trials.
“Larger, early‑stage clinical trials are now needed to determine whether these promising signs actually translate into tangible benefits for patients.”
Key Questions Answered:
A: Timing is everything. Most human trials to date have been short-term or involved patients who already had significant brain damage. This study suggests that because the drugs tackle the drivers (plaques and tangles), they should be tested in earlier stages of the disease, years before memory loss actually starts.
A: Scientists often use that term because Alzheimer’s is closely linked to insulin resistance in the brain. Since GLP-1 drugs were designed to fix insulin signaling in the body, they appear to “fix” the brain’s metabolism too, which helps it clear out toxic waste like amyloid.
A: Yes. While they haven’t “reversed” dementia yet, liraglutide has been shown to preserve brain glucose metabolism (the brain’s ability to use fuel), which is a key indicator that neurons are still functioning and healthy.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this AI and auditory neuroscience research news
Author: Jamie Forsyth
Source: Anglia Ruskin University
Contact: Jamie Forsyth – Anglia Ruskin University
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review” by Eve Corcoran, Michael Kettlety, Urwa Mogul, Jennifer Ndiforngwah Azah, and Simon C. Cork. Molecular and Cellular Neuroscience
DOI:10.1016/j.mcn.2026.104091
Abstract
The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review
Background
The incidence of Alzheimer’s disease (AD) is increasing globally but there are limited effective therapies available. Recently, evidence has demonstrated a role of GLP-1 receptor (GLP-1R) agonists, commonly used in the treatment of type 2 diabetes, may have therapeutic potential in AD. GLP-1R agonists have exhibited their neuroprotective role by targeting tau hyperphosphorylation and the accumulation of beta-amyloid (Aβ) plaques.
This systematic review aims to evaluate the effectiveness of liraglutide, semaglutide, exenatide and dulaglutide on AD pathology with a focus on the key biomarkers: hyperphosphorylated tau and Aβ.
Methods
A systematic literature search was conducted using PubMed, Embase and Cochrane Library. Inclusion criteria involved pre-clinical and clinical studies investigating the effects of GLP-1 agonists dulaglutide, liraglutide, semaglutide or exenatide on Aβ and tau pathology. Randomised and non-randomised studies were included. Exclusion criteria involved studies evaluating GLP-1R agonists other than those specified.
Results
This review examined thirty preclinical studies investigating the effects of four GLP-1 receptor agonists on Alzheimer’s disease pathology, particularly Aβ plaque accumulation and tau hyperphosphorylation. Most studies focused on liraglutide, which consistently reduced both Aβ and tau pathology in animal and cell models. Dulaglutide, although studied less frequently, consistently reduced tau phosphorylation and Aβ accumulation in mouse models while also improving cognitive outcomes. Semaglutide also showed largely positive effects with four studies reporting reduced Aβ or tau pathology, though one study reported no benefit.
Two clinical studies were also reviewed. A phase II trial of Exenatide showed reduced plasma Aβ42 in extracellular vesicles but not cognitive benefit. A smaller liraglutide trial demonstrated no reduction in Aβ burden or cognitive change though it preserved brain glucose metabolism. An EXSCEL trial showed significant changes in systemic inflammatory markers. While pre-clinical data has been encouraging, clinical evidence remains limited.
Conclusions
There is consistent preclinical evidence that GLP-1R agonists are effective in reducing Aβ levels and hyperphosphorylated tau. While the neuroprotective effect in preclinical studies is clear, clinical findings have so far failed to demonstrate an arresting effect on cognitive.
Registration
PROSPERO CRD420251029748.
